Atara Biotherapeutics (ATRA) Share-based Compensation (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported Share-based Compensation for 14 consecutive years, with $141.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 4952.87% year-over-year to $141.5 million; the trailing twelve-month figure through Jun 2026 stood at $141.5 million (up 634.16% YoY), and the FY2025 full-year result was $9.8 million, down 63.88% from the prior year.
• Share-based Compensation was little changed at $141.5 million in Q2 2026 per ATRA's latest filing, from $141.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $3.8 billion in Q3 2022 and bottomed at $1.2 million in Q3 2025.
• Historically, Share-based Compensation has averaged $429.8 million across 5 years, with a median of $12.6 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation soared 27385.67% in 2022, then slumped 99.82% in 2024.
• Over 5 years, Share-based Compensation stood at $11.4 million in 2022, then fell by 12.64% to $9.9 million in 2023, then sank by 41.11% to $5.8 million in 2024, then slumped by 74.05% to $1.5 million in 2025, then jumped by 9229.66% to $141.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $141.5 million, $141.3 million, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.